SPRY - ARS Pharmaceuticals Inc Net earnings per share (EPS TTM)
The growth foundation of ARS Pharmaceuticals (SPRY) is based on the creation of Neffy, the first painless alternative to injections for anaphylaxis. This rolling annual EPS chart confirms this potential, where -2.00 represents the current level of the metric. This breakthrough in emergency medicine is complemented by a stable staff of scientists and targeted reinforcement of the commercial division, ensuring confident business development.
Summary analytical data breakdowns for ARS Pharmaceuticals Inc (SPRY)
- share price and expert price forecast:
- market capitalization statistics:
- business book valuation details:
- debt obligations and liquidity statistics:
Total Debt to Capital ARS Pharmaceuticals|SPRY - Long-Term Debt to Capital|Short-Term Debt to Equity ARS Pharma|SPRY - Aggregate Debt Obligations|Debt to Book Capitalization Ratio ARS Pharmaceuticals, Inc.|SPRY - Long-Term Debt Volume|Company Current Liabilities ARS Pharmaceuticals|Quick Liquidity ars-pharma.com
- net income and valuation multiples indicators:
SPRY - Profit After Tax|Projected Future Earnings ARS Pharmaceuticals|SPRY - Company Value to Net Income|Forward P/E Multiple ARS Pharmaceuticals, Inc.|SPRY - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ARS Pharmaceuticals, Inc.|SPRY - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months ARS Pharmaceuticals|SPRY - Net earnings per share for the last 12 months|Quarterly EPS earnings growth ars-pharma.com|SPRY - Earnings growth in current year|Earnings growth forecast for next year ARS Pharmaceuticals
General company analysis:SPRY - ARS Pharmaceuticals
This indicator measures the company's aggregate net income distributed per common share over the last four quarters, allowing for an assessment of actual profit generation efficiency. For ARS Pharmaceuticals (SPRY), the rolling year net income per share trend verifies the commercial success of the neffy spray, confirming the transition from development to revenue scaling and the strengthening of market positions.
Competitors of ARS Pharmaceuticals
HLN: Net earnings per share for the last 12 months|kenvue.com - Earnings per share for the last four quarters|VRNA: Net earnings per share (EPS TTM)|Jyong Biotech Limited - Earnings per share for the trailing year|LGND (Ligand Pharma) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Amneal Corp AMRX|Earnings per share for the last twelve months Perrigo Company plc (PRGO)|ALVO (alvotech.com) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) LQDA (Liquidia)|Net earnings per share (EPS TTM) Galapagos N.V. GLPG|ANIP - Earnings per share for the last twelve months|Earnings per share for the trailing year MNKD (Afrezza)|Amphastar Pharmaceuticals (AMPH) - Earnings per share for the last twelve months|PCRX - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months TBPH|AQST: Earnings per share for the trailing year|Earnings per share for the last twelve months scPharmaceuticals Inc. (SCPH)|TECX: Earnings per one share for the last 12 months|Net earnings per share (EPS TTM) TNXP (Tonix Pharmaceuticals)|Earnings per share for the trailing year SXTC|Eupraxia Pharma - Net earnings per share (EPS TTM)|BHST - Net earnings per share (EPS TTM)|Invizyne Technologies, Inc. (EXOZ) - Earnings per share for the last twelve months|Oramed Pharmaceuticals Inc. - Earnings per share for the trailing year|Earnings per share for the last twelve months Entera Bio Ltd|Net earnings per share for the last 12 months ipatherapeutics.com (HYFT)|Net earnings per share (EPS TTM) ABVC|Net earnings per share (EPS TTM) Cumberland Pharmaceuticals Inc (CPIX)|Net earnings per share (EPS TTM) QNTM (Quantum BioPharma Limited)|FGEN - Net earnings per share for the last 12 months|Telomir Pharmaceuticals - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Rani Therapeutics|SNYR (synergychc.com) - Net earnings per share for the last 12 months|Rallybio (RLYB) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months LEXX|PULM (Pulmatrix Corporation) - Earnings per share for the last four quarters|Net earnings per share (EPS TTM) PTHL|Net earnings per share for the last four quarters aptorumgroup.com|Net earnings per share (EPS TTM) LYRA (Lyra Therapeutics)|IBO - Net earnings per share for the last 12 months|TNF Pharma - Net earnings per share (EPS TTM)|YCBD - Net earnings per share (EPS TTM)|PainReform Ltd. (PRFX) - Earnings per share for the last twelve months|CYTO (Altamira Therapeutics Ltd.) - Earnings per share for the last twelve months|Earnings per share for the last twelve months Lipella Pharmaceuticals, Inc.|OptiNose Inc (OPTN) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Pieris (PIRS)|Net earnings per share for the last four quarters Procaps Group Corp|Earnings per share for the last twelve months Petros Pharmaceuticals PTPI|QLI (qlsyy.net) - Earnings per one share for the last 12 months|SLRN - Earnings per share for the last twelve months|Earnings per share for the trailing year TFFP (TFF Pharmaceuticals Inc.)
